The FDA has issued a voluntary nationwide recall of papaverine hydrochloride injection from American Regent due to contamination with visible particulate matter, including glass and paraformaldehyde. If you or a loved one received this injection, checking your lot number immediately is critical, as the contaminated particles could potentially travel through blood vessels and cause serious complications including stroke.

What Is Papaverine and Why Is This Recall Happening?

Papaverine hydrochloride injection is a medication used to treat certain circulatory and urological conditions. The FDA's concern centers on the discovery of visible particulate matter in one specific lot. According to the agency, if particulate matter enters the bloodstream through injection, it could lodge in blood vessels supplying the heart, lungs, or brain, potentially causing stroke or death.

The recalled product is Papaverine Hydrochloride Injection, USP (60 mg/2 mL), Lot 25202, with NDC 0517-4002-25 and an expiration date of November 30, 2026. As of the recall announcement, the FDA had not received any reports of adverse events related to this contamination, but the agency is taking a precautionary approach.

How to Check If You Have the Recalled Lot?

The first step for patients and caregivers is to locate the vial or packaging and verify the lot number. Look at the label on your papaverine injection bottle or box and match it against the recalled lot information. If you find that you have Lot 25202, stop using it immediately and contact your healthcare provider for guidance on next steps.

• Check the Label: Look for the lot number and NDC (National Drug Code) on the vial or box. The recalled lot is 25202 with NDC 0517-4002-25.
• Stop Using It: If you have the affected lot, do not administer any additional doses. Keep the packaging and vial so your healthcare team can identify it if needed.
• Contact Your Clinician: Even if you feel well, notify your healthcare provider or pharmacist that you may have received Lot 25202 so they can document it and advise on monitoring.
• Save the Packaging: Retain all original packaging and the vial itself, including lot details, for your healthcare team's records.

What Symptoms Should Trigger Emergency Care?

Because the contamination could potentially cause blood vessel blockage, patients should be alert to stroke symptoms. The CDC identifies specific warning signs that require immediate emergency care. If you or someone who received this injection develops any of these symptoms, call 911 right away.

• Face Drooping: One side of the face droops or feels numb. Ask the person to smile and look for asymmetry.
• Arm Weakness: One arm drifts downward or feels weak. Ask the person to raise both arms and check if one arm cannot stay elevated.
• Speech Problems: Speech becomes slurred, strange, or difficult to understand. Ask the person to repeat a simple phrase like "The sky is blue."
• Sudden Trouble Walking or Balance: Loss of coordination or difficulty maintaining balance without a clear cause.
• Sudden Vision Changes: Blurred vision, double vision, or sudden loss of sight in one or both eyes.
• Sudden Numbness or Weakness: Particularly on one side of the body, often accompanied by tingling sensations.
• Sudden Confusion: Difficulty understanding others or expressing yourself clearly.
• Severe Headache: A sudden, intense headache with no known cause, especially if accompanied by other symptoms.

The key is timing. Note when symptoms first appear and seek emergency evaluation immediately. While harm is not guaranteed from exposure to this lot, the potential risk warrants prompt medical attention if any concerning signs develop.

What Should Healthcare Facilities Do?

Clinics and healthcare facilities that may have received papaverine from American Regent need to take immediate inventory action. Facilities should locate all papaverine vials in stock, verify the lot number and NDC against the recall notice, and quarantine any vials matching Lot 25202.

Healthcare providers should document which lots were received and used, including details about distribution and administration. This documentation helps track which patients may have received the contaminated product. Facilities should also coordinate with their distributor or manufacturer regarding return or discard procedures and inform all relevant staff about the specific lot details so the correct vials are identified during the recall period.

How to Report Problems Related to the Recall?

If you believe you experienced a health problem related to the recalled papaverine injection, the FDA encourages reporting through its MedWatch voluntary reporting system. Healthcare professionals can submit a report using FDA Form 3500, while patients and consumers can use FDA Form 3500B. Reports can be submitted online or by downloading and submitting the appropriate form.

Reporting helps the FDA track any adverse events and strengthens the safety database for future regulatory decisions. Even if you're unsure whether your symptoms are related to the recalled product, reporting provides valuable information to health authorities.

Key Takeaways for Patients and Families

This recall is a precaution based on contamination discovered during quality control, not proof that every dose caused injury. However, the potential for serious complications means vigilance is warranted. Check your papaverine vials now if you have them, contact your healthcare provider if you have the recalled lot, and seek emergency care immediately if stroke-like symptoms develop after receiving an injection.

Keep your follow-up appointments with your healthcare provider and maintain open communication about any symptoms or concerns. If you have questions about whether your specific vial is affected or what monitoring you should undergo, your clinician or pharmacist is the best resource for personalized guidance based on your individual health situation.